Autolus Therapeutics Q2 EPS $(0.18) Beats $(0.24) Estimate, Sales $20.923M Beat $12.905M Estimate

Autolus Therapeutics (NASDAQ: AUTL) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 25 percent. This is a 18.18 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $20.923 million which beat the analyst consensus estimate of $12.905 million by 62.13 percent.